Background-Although the dominant product of vascular Cyclooxygenase-2 (COX-2), prostacyclin (PGI 2 ), restrains atherogenesis, inhibition and deletion of COX-2 have yielded conflicting results in mouse models of atherosclerosis. Floxed mice were used to parse distinct cellular contributions of COX-2 in macrophages and T cells (TCs) to atherogenesis. Methods and Results-Deletion of macrophage-COX-2 (Mac-COX-2KOs) was attained with LysMCre mice and completely suppressed lipopolysaccharide-stimulated macrophage prostaglandin (PG) formation and lipopolysaccharide-evoked systemic PG biosynthesis by Ϸ30%. Lipopolysaccharide-stimulated COX-2 expression was suppressed in polymorphonuclear leukocytes isolated from MacKOs, but PG formation was not even detected in polymorphonuclear leukocyte supernatants from control mice. Atherogenesis was attenuated when MacKOs were crossed into hyperlipidemic low-density lipoprotein receptor knockouts. Deletion of Mac-COX-2 appeared to remove a restraint on COX-2 expression in lesional nonleukocyte (CD45-and CD11b-negative) vascular cells that express vascular cell adhesion molecule and variably ␣-smooth muscle actin and vimentin, portending a shift in PG profile and consequent atheroprotection. Basal expression of COX-2 was minimal in TCs, but use of CD4Cre to generate TC knockouts depressed its modest upregulation by anti-CD3⑀. However, biosynthesis of PGs, TC composition in lymphatic organs, and atherogenesis in low-density lipoprotein receptor knockouts were unaltered in TC knockouts. Conclusions-Macrophage-COX-2, primarily a source of thromboxane A 2 and prostaglandin (PG)E 2 , promotes atherogenesis and exerts a restraint on enzyme expression by lesional cells suggestive of vascular smooth muscle cells, a prominent source of atheroprotective prostacyclin. TC COX-2 does not detectably influence TC development or function or atherogenesis in mice. (Circulation. 2010;121:2654-2660.)
L ipid products of the prostaglandin (PG) G/H synthase enzymes (colloquially known as cyclooxygenase [COX] -1 and -2) are mediators of pain, fever, and inflammation 1 and the primary targets of nonsteroidal antiinflammatory drugs. However, deletion of either COX-1 or the more readily inducible COX-2 may promote, dampen, or leave unaffected the inflammatory response in diverse rodent models. 2 Although nonsteroidal antiinflammatory drugs specific for inhibition of COX-2 are less likely to cause serious gastrointestinal adverse events than drugs that inhibit both COXs together, placebo-controlled trials have demonstrated that they also confer a cardiovascular risk attributable to suppression of cardioprotective COX-2 products, particularly prostacyclin (PGI 2 ). 3 
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Deletion, mutational inactivation, knockdown, and pharmacological inhibition of COX-2 predispose mice to thrombogen-esis and an elevation of blood pressure, 3, 4 effects also seen in mice lacking the PGI 2 ligated, I prostanoid (IP) receptor. 3 However, although deletion of the IP fosters initiation and early development of atherosclerosis in hyperlipidemic mice, 5, 6 COX-2 deletion or its pharmacological inhibition has yielded contrasting results. 7 It has been speculated that this may reflect the differential impact of COX-2 inhibition on cells with divergent effects on atherogenesis, contrasting effects of COX-2 inhibition on atherogenesis at varied stages of disease evolution, and varied degrees of selectivity for COX-2 among the drug regimens used. 7 We generated mice in which the COX-2 gene is flanked by loxP sites 8, 9 to permit cell-specific analysis of its contribution to the inflammatory response in vivo. Macrophages are fundamental to the inflammatory response, mediating phagocytosis, releasing cytokines, and serving as antigen-presenting cells. 10 Activation of macrophages by lipopolysaccharide markedly upregulates COX-2 and augments release of its major products, thromboxane (Tx) A 2 and PGE 2 . 11 The discrete contribution of macrophage-COX-2 (Mac-COX-2) to inflammation has thus far been approached indirectly. Transfer of COX-2-deficient fetal liver cells to lethally irradiated mice retards atherogenesis. 12, 13 Here, COX-2 deficiency confined to myeloid cells, including macrophages (Mac-COX-2 Knock Outs [KOs]), was achieved by mating the floxed mice with those carrying the LysMCre recombinase. 14 PGs also influence immune regulation by modulating the development and functions of dendritic cells, T and B cells. 2, 15, 16 We have previously reported that products of both COX-1 and COX-2 influence T-cell development in the thymus 17, 18 and that PGs can exert contrasting effects on the function of mature T cells. 2 However, the cellular origin of such lipids has long been a source of debate. Although subpopulations of T cells that express COX-2 have been identified, 19 -24 the evidence that T cell-derived PGs subserve an autocrine function remains inconclusive. 19, 23, 25 Here, we crossed floxed mice with CD4-Cre to deplete COX-2 in T cells and examine its effect on T-cell development and function and in atherogenesis.
Methods

Generation of Mac-COX-2 KOs
Mice with the COX-2 gene flanked with 2 LoxP sites, COX-2 f/f mice, were generated as described 8,9 on a mixed 129Sv/B6 background (Ϸ75% B6, Ϸ25% 129Sv) and crossed with B6 LysMCre ϩ/ϩ mice to obtain LysMCre ϩ/Ϫ /COX-2 f/ϩ mice, which then were backcrossed with COX-2 f/f to create LysMCre ϩ/Ϫ /COX-2 f/f mice. These mice were intercrossed to generate homozygous LysMCre ϩ/ϩ / COX-2 f/f mice as Mac-COX-2 KO and COX-2 f/f mice as their littermate wild-type (WT) controls. LysMCre ϩ/ϩ /COX-2 f/f mice were further crossed with B6 low-density lipoprotein receptordeficient (LdlR Ϫ/Ϫ ) mice (The Jackson Laboratory, Bar Harbor, Me) to obtain LysMCre ϩ/Ϫ /COX-2 f/ϩ /LdlR ϩ/Ϫ mice. These mice were intercrossed to create the LysMCre ϩ/Ϫ /COX-2 f/f /LdlR Ϫ/Ϫ genotype. Intercrossing LysMCre ϩ/Ϫ /COX-2 f/f /LdlR Ϫ/Ϫ mice generated Ly-sMCre ϩ/ϩ /COX-2 f/f /LdlR Ϫ/Ϫ mice (Mac-COX-2 KO/LdlR Ϫ/Ϫ ) and their COX-2 f/f /LdlR Ϫ/Ϫ littermate controls (WT/LdlR Ϫ/Ϫ ), which were both fed a high-fat diet (HFD; 0.2% cholesterol/21% saturated fat; formula TD 88137, Harlan Teklad, Indianapolis, Ind) from 8 weeks of age for either 3 or 6 months. Genotyping by polymerase chain reaction was derived from the Wang et al 9 study for the floxed COX-2 gene and from the Jackson Laboratory protocol for LdlR. LysMCre genotyping used primer pair 5ЈCTT GGG CTG CCA GAA TTT CTC (LysM1) and 5ЈTTA CAG TCG GCC AGG CTG AC for the detection of the WT allele and primer pair LysM1 and 5ЈCCC AGA AAT GCC AGA TTA CG for the LysMCre allele.
Generation of T Cell-Specific COX-2-Deficient Mice
The floxed mice described above were crossed with B6 CD4Cre mice (Taconic, Hudson, NY) to obtain CD4Cre/COX-2 f/ϩ mice, which then were backcrossed with COX-2 f/f to create CD4Cre/COX-2 f/f mice. These mice were crossed with COX-2 f/f to generate CD4Cre/COX-2 f/f mice as T cell-specific COX-2-deficient (TCKO) mice and COX-2 f/f mice as WT. These mice were further crossed with B6 LdlR Ϫ/Ϫ mice (The Jackson Laboratory) to obtain CD4Cre/ COX-2 f/f /LdlR Ϫ/Ϫ mice and COX-2 f/f /LdlR Ϫ/Ϫ , which were crossed to create the CD4Cre Ϫ/Ϫ /COX-2 f/f /LdlR Ϫ/Ϫ (T-COX-2 KO/ LdlR Ϫ/Ϫ ) and COX-2 f/f /LdlR Ϫ/Ϫ littermate controls (WT/LdlR Ϫ/Ϫ ). These mice were fed the same HFD as the Mac-COX-2 KOs. CD4Cre genotyping used primer pair 5ЈCGA TGC AAC GAG TGA TGA GG and 5ЈGCA TTG CTG TCA CTT GGT CGT. To detect COX-2 deletion, primer pairs 5ЈTTT GCC ACT GCT TGT ACA GCA ATT and 5ЈTGA GGC AGA AAG AGG TCC AGC CTT were used. All animals in this study were housed following guidelines of the Institutional Animal Care and Usage Committee of the University of Pennsylvania. All experimental protocols were approved by the Institutional Animal Care and Usage Committee.
Peritoneal Macrophage Culture
Peritoneal macrophages were collected 4 days after intraperitoneal injection of 0.5 mL of 10% thioglycollate. Nonadherent cells were removed after 2 hours of incubation. Adherent cells were treated with lipopolysaccharide (Sigma Chemicals, St Louis, Mo) 5 g/mL for 6 hours for RNA and 12 hours for protein and supernatant collection.
Mass Spectrometric Analysis of Prostanoids and Their Metabolites
Prostanoids or their metabolites were measured by mass spectrometry as described previously. 11, 26 Briefly, macrophage production of PGE 2 , prostaglandin (PG)D 2 , TxA 2 , and PGI 2 was determined by quantification of PGE 2 , PGD 2 , TxA 2 , and 6-keto prostaglandin (PG)F 1 ␣ in cell culture supernatants, respectively, and normalized with protein. Systemic production of PGE 2 , PGD 2 , TxA 2 , and PGI 2 was determined by quantification of their major urinary metabolites (7- 
Quantification of Atherosclerosis
Mouse aortic trees were prepared and stained and atherosclerotic lesions were quantified as previously described. 11 Briefly, mice on an LdlR Ϫ/Ϫ background fed an HFD for 3 or 6 months were euthanized. The entire aorta from the aortic root to the iliac bifurcation was collected and fixed in 10% buffered formalin (Fisher Scientific, Hampton, NH). Adventitial fat was removed. The aorta was opened longitudinally, stained with Sudan IV (Sigma Chemicals), and pinned down on black wax to expose the intima. The extent of atherosclerosis (Phase 3 Imaging Systems, Glen Mills, Pa) was determined by the en face method: lesion area percentage to the entire intimal area.
Immunohistochemical Examination of Lesion Morphology
Mouse hearts were embedded in optical coherence tomography compound, and 8-m serial sections of the aortic root were mounted on masked slides (Carlson Scientific, Peotone, Ill) for analysis of lesion morphology. Briefly, acetone-fixed and peroxidase-quenched sections were blocked with goat IgG (Jackson ImmunoResearch, West Grove, Pa), incubated with primary antibodies FITC-conjugated mouse anti-␣smooth muscle actin (␣-SMA) clone 1A4 (Sigma Chemicals), and then incubated with biotinylated goat anti-FITC (Vector Laboratories, Burlingame, Calif) or rabbit antimouse COX-2 antibody (Cayman Chemicals, Ann Arbor, Mich), followed by biotinylated goat antirabbit Ig (Vector Laboratories) secondary antibody. Serial sections were stained with biotinylated rat antimouse vascular cell adhesion molecule-1/ CD106 (BD Biosciences, San Jose, Calif), biotinylated rat antimouse CD11b (BD Biosciences), or rat antimouse CD45 (BD Biosciences), followed by incubation with biotinylated goat antirat Ig secondary antibody (Jackson ImmunoResearch,). Alternatively, serial sections were blocked with rabbit IgG (Jackson ImmunoResearch,) and then incubated with goat antivimentin (Sigma Chemicals) or antimouse active caspase 3 (Abcam, Cambridge, Mass), followed by biotinylated rabbit antigoat (Jackson ImmunoResearch,) and biotinylated goat antirabbit Ig (Vector Laboratories) secondary antibodies, respectively.
All reactions were amplified with Vectastain ABC avidin-biotin (Vector Laboratories) and developed with diaminobenzidine (Dako, Carpinteria, Calif). All sections were counterstained with Gill's Formulation No. 1 hematoxylin (Fisher Scientific). Isotype-matched controls were run in parallel and showed negligible staining in all cases.
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Statistical Analysis
When comparisons between genotypes involved both male and female genders, the data were first subjected to 2-way ANOVA.
Nonparametric ANOVA was performed out of concern for the parametric assumptions of equal variances and normality; 
Results
Macrophage Contribution to Systemic Biosynthesis of Prostanoids
Stimulation of peritoneal macrophages with lipopolysaccharide ex vivo markedly augmented expression of COX-2 ( Figure 1 ) and formation of PGs (Figure 2A ). Expression of lipopolysaccharide-stimulated COX-2 mRNA (Ϸ98%) and proteins (Ϸ95%) was reduced in the Mac-COX-2 KOs ( Figure 1A and B). A similar reduction was observed in bone marrow-derived macrophages ( Figure IA in the online-only Data Supplement) but not in vascular smooth muscle cells (VSMCs; Figure IC in the online-only Data Supplement). The dominant products of peritoneal macrophages, TxA 2 and PGE 2, were markedly depressed in Mac-COX-2 KOs, as were the less abundant products, PGI 2 and PGD 2 (Figure 2A ). Although the abundance and profile of the prostanoids differed somewhat in bone marrowderived macrophages, the levels were again markedly suppressed in the KOs ( Figure IB in the online-only Data Supplement). The impact of Mac-COX-2 deletion on prostanoid biosynthesis was also assessed by measurement of the increment in major urinary metabolites after lipopolysaccharide. Stimulated, systemic biosynthesis of prostanoids was significantly depressed 30% to 38% on average in the Mac-COX-2 KOs ( Figure 2B ). LysMCre mice express Cre recombinase in all myeloid cells, including macrophages, neutrophils, and some dendritic cells. Although induction of COX-2 was evident in WT neutrophils ( Figure II in the online-only Data Supplement), prostanoid generation was not detectable with or without lipopolysaccharide stimulation in either WT or KO cells. Similarly, COX-2 deletion was detected in only Ϸ15% of the CD11c ϩ splenic dendritic cells, 14 so the dominant impact in the KOs is on Mac-COX-2.
Modest Expression of COX-2 mRNA in T Cells
Specific deletion of the COX-2 gene in T cells in TCKO mice was confirmed by genomic polymerase chain reaction ( Figure  IIIA Notably, a faint band with a slightly larger molecular weight to COX-2 was expressed under stimulated conditions; this protein persisted in cells from mice with global deletion of COX-2. Consistent with the absence of COX-2 protein, generation of prostanoids remained at the limit of detection (despite the addition of exogenous substrate) in both WTs and TCKOs.
T-Cell COX-2 Does Not Influence T-Cell Development or Function in Mice
Because both COXs have been implicated in regulating T-cell development in the thymus, 17, 18 we sought to determine whether this might reflect in part an autocrine function of T-cell COX-2. Adult mouse thymus, lymph nodes, and spleen revealed no macroscopic or microscopic difference between WTs and TC-KOs in size or morphology ( Figure IVA 
Macrophage COX-2 Accelerates Atherogenesis and Restrains Enzyme Expression in a Population of Nonmacrophage Lesional Cells
Atherosclerotic lesion burden ( Figure 3A) was reduced significantly in Mac-COX-2 KOs by Ϸ25% in both genders after 6 months on an HFD. Plasma lipids were not affected by Mac-COX-2 deletion in either gender ( Figure V in the online-only Data Supplement). Mac-COX-2 is a potential source of inflammatory modulators of adipocyte function 27, 28 and is markedly upregulated when fibroblasts are induced to differentiate into adipocytes. 29 Neither weight gain nor percentage body fat ( Figure VIA and VIB in the online-only Data Supplement) measured after 3 or 6 months on the HFD differed between controls and Mac-COX-2 KOs backcrossed onto an LdlR Ϫ/Ϫ background. Lesional analysis was performed at 3 months because genotypic distinctions in morphology are often less evident at more advanced stages of atherogenesis. 11 Both WT and MacKO lesions were already advanced, with prominent atheromatous cores and fibrotic caps. WT lesions showed widely dispersed cells staining positive for COX-2 ( Figure 4A and 4B) , whereas a more discrete intimal population of cells, with a biased distribution toward the intima-media border, stained for COX-2 in the MacKO lesions ( Figure 4C and 4D) . These latter COX-2-positive cells were distinct from CD45-positive leukocytes, including CD11b-positive macrophages on serial sections ( Figure 4E and 4F versus 4G and 4H, plus Figure VIIA and VIIB in the online-only Data Supplement). Although they are distinct from cells stained with macrophage markers, their precise origin is unclear. They are uniformly negative for the pan-leukocyte marker CD45 but stain positive for vascular cell adhesion molecule-1 (Figure 4L through 4N) and resemble a previously reported proliferative subset of lesional VSMCs. 30, 31 These cells were heterogeneous with respect to the expression of . Although analysis of PG formation by these lesional cells is not technically possible, if they proved to be VSMCs, upregulation of COX-2 at the expense of that in macrophages would likely favor a shift toward formation of atheroprotective PGI 2 11 . There was no apparent alteration in the lesional expression of COX-1 in the Mac-COX-2 KOs ( Figure  VIIIA and VIII in the online-only Data Supplement). Apoptosis, reflected by staining for activated caspase 3, was augmented in lesions from Mac-COX-2 KOs ( Figure 5 ).
T-Cell COX-2 Does Not Influence Atherogenesis
In contrast to the functional importance of COX-2 in myeloid cells, deletion of COX-2 in T cells had no detectable effect on either atherogenesis ( Figure 3B 
Discussion
Randomized trials have provided evidence that nonsteroidal antiinflammatory drugs selective for inhibition of COX-2 confer a cardiovascular hazard explicable in terms of sup-pression of cardioprotective products of COX-2, particularly PGI 2 . 3 Inhibition or deletion of COX-2 or deletion of the IP augments the response to thrombogenic stimuli, 4 elevates systemic 4 and pulmonary 32, 33 blood pressure, disrupts vascular remodeling, 34 and predisposes to cardiac failure and arrhythmogenesis 9 in rodents. However, although deletion of the IP retards atherogenesis, 5,6 deletion or inhibition of COX-2 may accelerate, retard, or leave unaltered atherogenesis. 7 Many cell types, each of which differs in their spectrum of COX-2 products, contribute to or restrain atherogenesis, so the timing of intervention, as well as efficiency and selectivity of enzyme inhibition, might contribute to the variability of the results in rodents. Meantime, despite its established cardiovascular risk 35 and the retraction of articles suggesting that upregulation of COX-2 predisposed to destabilization of atherosclerotic plaques in humans, 36, 37 a large randomized trial is underway to determine whether the COX-2 inhibitor celecoxib might more favorably influence cardiovascular outcomes than other nonsteroidal anti-inflammatory drugs. 38 Given the contrasting impact of prostanoids formed by COX-2 in different cells on atherogenesis, we have initiated analysis of the functional importance of COX-2 deletion in discrete cell types on disease evolution. In these studies, using LysMCre mice, we found evidence that Mac-COX-2 accelerates atherogenesis in the LdlR Ϫ/Ϫ mice. A surprising finding was that although lesional Mac-COX-2 was indeed depleted in the KOs, COX-2 was upregulated in a subset of cells and negative for the macrophage marker Cd11b and the panleukocyte marker CD45. The origin of these cells remains to be defined, but they have some features of VSMC morphology: they stain positive for vascular cell adhesion molecule and are heterogeneous with respect to expression of ␣-SMA and vimentin. We and others have previously shown that prostanoids such as PGI 2 and PGE 2 may upregulate COX-2. 39, 40 Here, it appeared that either direct products of Mac-COX-2 or compounds indirectly regulated by the enzyme act to restrain expression of COX-2 in this subset of VSMCs. This interplay of COX-2 expression between different cell types is reminiscent of the upregulation of COX-2 that we observed in cardiac fibroblasts consequent to cardiomyocyte enzyme deletion. 9 Here, this shift in enzyme expression may have had a functional consequence. Thus, although the dominant products of COX-2 in macrophages are TxA 2 and PGE 2 , both of which can accelerate atherogenesis, 7,11 PGI 2 is the major COX-2 product of VSMCs and has the opposite effect. For now, this remains speculative. Harvesting such lesional cells in quantities to document product formation is not technically possible. Addressing the hypothetical importance of augmented formation of PGI 2 in these mice will be pursued with pharmacological antagonism and genetic deletion of the IP. Narasimha et al 41 have recently reported a failure of Mac-COX-2 deletion to modify atherogenesis in apolipoprotein E-deficient mice. COX-2 expression in the lesions of their MacKOs was observed, but the cells involved were not characterized.
Although the impact of prostanoids on T-cell development and function is well established, the possibility that T cells might themselves generate prostanoids to subserve an autocrine function remains unresolved. Evidence for T-cell expression of COX-2 but not of prostanoid product formation has been obtained in autoimmune diseases. 20, 42 Although PGE 2 production was detected coincident with COX-2 expression in FOXP3 ϩ CD4 ϩ CD25 ϩ adaptive regulatory T cells (T Radapt ), 23 nonsteroidal antiinflammatory drugs of varied selectivity for inhibition of COX-2 failed to modulate T-cell activation, proliferation, or susceptibility to apoptosis. 25 The present results exclude a major impact of T-cell COX-2 on T-cell development or function in mice. Furthermore, despite the importance of T cells in atherogenesis, 43, 44 there was no detectable effect of COX-2 deletion in T cells on either weight gain or lesion development in hyperlipidemic mice.
Conclusions
Mac-COX-2 promotes atherogenesis in LdlR Ϫ/Ϫ mice, while the enzyme in T lymphocytes has no impact on disease evolution. Targeted deletions of COX-2 are likely to reveal contrasting functional effects of COX-2 in distinct cell types in complex, multicellular diseases such as atherosclerosis.
